MedTrace Logo

Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease

NCT02148718 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2018-03-01

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the rapidity of onset of clinical response to adalimumab therapy in patients with luminal Crohn's disease.

Conditions

  • Moderate to Severe Crohn's Disease

Interventions

BIOLOGICAL

adalimumab

Adalimumab pre-filled syringe, administered by subcutaneous injection

Sponsors & Collaborators

  • Laboratorio Echevarne

    collaborator INDUSTRY

  • Pivotal S.L.

    collaborator INDUSTRY

  • AbbVie

    lead INDUSTRY

Principal Investigators

  • Ignacio Marín, PhD · Hospital General Universitario Gregorio Marañon

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2016-08-31
Completion
2017-01-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02148718 on ClinicalTrials.gov